Common Diabetes Drugs Associated With Increased Risk Of Death
Follow all of ScienceDaily's latest research news and top science headlines ! Common diabetes drugs associated with increased risk of death Compared to another popular drug, three widely used diabetes medications are associated with a greater risk of death, a large new analysis finds. Compared to another popular drug, three widely used diabetes medications are associated with a greater risk of death, a large new analysis finds. The results were presented June 25 at The Endocrine Society's 94th Annual Meeting in Houston. The drugs, glipizide, glyburide, and glimepiride, are known as sulfonylureas, which help decrease blood-sugar levels among type 2 diabetes patients by stimulating the pancreas to produce insulin. In the past, these medications were considered comparable to one another in terms of effectiveness and safety. Recently, however, research has shown some sulfonylureas may be safer than others. These findings led to this latest research, which compared them to another type of blood-sugar-reducing drug known as metformin. All four medications are available under low-cost, generic labels. "We have clearly demonstrated that metformin is associated with a substantial reduction in mortality risk, and, thus, should be the preferred first-line agent, if one has a choice between metformin and a sulfonylurea," said study lead author Kevin M. Pantalone, D.O., an endocrinologist at Summa Western Reserve Hospital in Cuyahoga Falls, OH, who conducted this study in conjunction with a team of researchers from Cleveland Clinic in Cleveland, OH. In the United States, nearly 26 million people, or 8 percent of the population, have diabetes, according to the Centers for Disease Control and Prevention. Many of these patients also have other underlying medical conditions, including Continue reading >>
Description And Brand Names
Drug information provided by: Micromedex US Brand Name Metaglip Descriptions Glipizide and Metformin combination is used to treat high blood sugar levels that are caused by a type of diabetes mellitus or sugar diabetes called type 2 diabetes. Normally, after you eat, your pancreas releases insulin to help your body store excess sugar for later use. This process occurs during normal digestion of food. In type 2 diabetes, your body does not work properly to store the excess sugar and the sugar remains in your bloodstream. Chronic high blood sugar can lead to serious health problems in the future. Proper diet is the first step in managing type 2 diabetes but often medicines are needed to help your body. With two actions, the combination of glipizide and metformin helps your body cope with high blood sugar. Glipizide stimulates the release of insulin from the pancreas, directing your body to store blood sugar. Metformin has three different actions: it slows the absorption of sugar in your small intestine; it also stops your liver from converting stored sugar into blood sugar; and it helps your body use your natural insulin more efficiently. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Tablet Copyright © 2018 Truven Health Analytics Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Continue reading >>
- Caffeinated and Decaffeinated Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review and a Dose-Response Meta-analysis
- Insulin, glucagon and somatostatin stores in the pancreas of subjects with type-2 diabetes and their lean and obese non-diabetic controls
- St. Luke’s Spotlights Critical Link Between Type 2 Diabetes and Heart Disease in Partnership with Boehringer Ingelheim and Eli Lilly and Company
'cautionary Lesson' About Metformin For Pancreatic Cancer
'Cautionary Lesson' About Metformin for Pancreatic Cancer PHILADELPHIA The great hope that the diabetes drug metformin will be a life-extending treatment for pancreatic cancer looks a bit shaky, according to a new study. Hope has been rooted in a couple of factors, suggested lead author Roongruedee Chaiteerakij, MD, PhD, from the Mayo Clinic Cancer Center in Rochester, Minnesota. First, there is the profound need for new treatment. Pancreatic cancer has a median survival of only 5 to 8 months, and an overall 5-year survival rate of only 6%, she said. Second, multiple epidemiologic studies have suggested there is a reduction in cancer mortality , including pancreatic cancer mortality, with metformin. This has led to a flurry of at least 20 investigations of metformin in a variety of cancers. In fact, there are currently 10 clinical trials on the use of metformin in the treatment of pancreatic cancer that are ongoing or that have not finalized and reported their data, Dr Chaiteerakij told reporters during a press conference here at the American Association for Cancer Research 2015 Annual Meeting. However, the original epidemiologic evidence that inspired those trials might have been flawed, she explained. In fact, results from a study by she and her colleagues serve as a "cautionary lesson" about the shortcomings of standard epidemiologic data. In patient databases, metformin exposure is "commonly characterized as simply" ever or never, she pointed out. This could "potentially introduce unintended biases," she said. Most notably, there could be patient-selection bias because ever users might be, collectively, healthier and living longer than those who never got a prescription for the drug. Dr Chaiteerakij and her colleagues investigated the matter with a retrospective co Continue reading >>
New Research On Pancreas Burnout By Oral Meds?
Personally, after I read about these types of drugs, I stopped taking Glipizide and decided to stick to Metformin and insulin. The side effects are well known, they work, and you can adjust the dose based on your needs. Are you currently taking one of these drugs? How is that working for you? Thank you for your comment. My BS are always under 6.1, for 20 years. Last a1c was 5.7. Now on 1 mg glimepiride and 2500 metformin, so control is good. No side effects. I want to have some beta cells if they are later needed for some cure some day. Age 68 now. Trying to come off the glimepride with more weight loss/exercise. Don't know if it is pathway damage or decrease in betas. Last c peptide showed still producing. I try to follow folks like Dr. Larry Distiller, researchgate.net etc, but there is no definitive answer yet it seems. Daytona, it seems that you are confusing two different types of drugs. Your links are for the GLP-1 Agonist type of drugs while Glyburide is a sulfonylurea. I took a sulfonylurea called Glipizide for several years and it was possible for me to get off of it entirely by changing to LCHF. Jenny Ruhl used to state that sulfonylureas were tee cause for killing beta cells but in her more recent book she said that the newer research caused her to change that view. The biggest cause of damage to beta cells is high blood sugar. In my opinion it is extremely hard to control blood sugar by using any type of drug. There is no way to regulate the dose of each time you take it and the idea that you can just take two pills a day and cover highs and lows just doesn't work. This is why the ADA wants PWD to consume higher levels of carbs for each meal and snacks in between. Even though my A1c was in the 6% range I knew that meals could raise my bg to over 300 but my Continue reading >>
Glipizide Concerns?
I just finished reading Dr Bernstein's Diabetes Solution and I am concerned about the glipizide that my doctor has me taking currently. Dr Bernstein seems very sure that glipizide can cause burn out of the pancreas's ability to produce insulin. I am seeing my doctor next month and would like to discuss this with him so that I understand more fully the risks. I was diagnosed last May after being told for years that I was borderline diabetic. I am a big ex-football tackle (6'2", 350+) who has a sedentary job. I have lost around 35 pounds since then and am beginning to exercise more. My fasting bg has gone from around 150+ to averaging around 90 in the last month. My A1C last May was 7.0 and the latest test in December was 6.3. I have another test in April that I'm pretty sure will show marked improvement in my A1C since I have been very strictly following a low-carb diet for the last 2 months and have had much better bg stability and numbers. With your diet and weight loss, you may be able to control blood sugar on Metformin alone. An average of 90 is really excellent. Also, you're not on the full dose of Metformin, so if you're concerned about your blood sugar going up after stopping the Glipizide, you could ask your doctor to max out your dose. If that point you find you don't need as much Metformin, then you work with your doctor on decreasing your dose slowly until you find the level that works for you. And, of course, you can always increase as needed rather than preemptively upping the dose. The American Academy of Physicians came out with remcomendations last week against drugs like Glipizide unless all other drugs fail to work. They were more concerned about hypos, but over stimulation of insulin is a possibility leading to quicker beta cell burnout. 115 pounds, Continue reading >>
Glipizide, Insulin, Pancreas Longevity
Registration is fast, simple and absolutely free so please,join our community todayto contribute and support the site. This topic is now archived and is closed to further replies. Since I didn't receive any response to this question, I thought I'd move it up to the top and try again. Glipizide, as I understand it, stimulates production of insulin. That being the case, does the production of more insulin via glipizide have a long-term effect, such as wearing out one's pancreas or perhaps lessening the production of insulin in the future? My opinion: by the time you show signs of Type 2 D -- a Dx of Type 2 D or Pre-D -- your Pancreas has already been working flat out for possibly years, to overcome Insulin Resistance (IR), so adding to it's workload does not seem to make much sense. An overworked Pancreas is likely to burn out and stop working, sooner or later. So how do you reduce the load on the Pancreas? Exercise seems to help with IR, so does weight-loss, and so does reducing the amount of carbs eaten... less carbs/sugars = less need for insulin. It is also worth at least considering injecting insulin.. even if it is only temporary until, for example, you achieve the weight-loss. My opinion: by the time you show signs of Type 2 D -- a Dx of Type 2 D or Pre-D -- your Pancreas has already been working flat out for possibly years, to overcome Insulin Resistance (IR), so adding to it's workload does not seem to make much sense. An overworked Pancreas is likely to burn out and stop working, sooner or later. So how do you reduce the load on the Pancreas? Exercise seems to help with IR, so does weight-loss, and so does reducing the amount of carbs eaten... less carbs/sugars = less need for insulin. It is also worth at least considering injecting insulin.. even if it is only Continue reading >>
Common Side Effects Of Glucotrol (glipizide) Drug Center - Rxlist
Tell your doctor if you experience serious side effects of Glucotrol including easy bruising or bleeding (nosebleeds, bleeding gums), tiredness, shortness of breath, upper stomach pain, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); pale skin, fever, confusion; or throbbing headache, severe nausea and vomiting, fast or pounding heartbeats, sweating or thirst, or feeling like you might pass out. Glucotrol is available in 5 and 10 mg strength tablets. The usual starting dose is 5 mg about 30 min before breakfast. Serious side effects of Glucotrol include hypoglycemia, jaundice, liver damage, fever, bleeding or bruising, skin changes, SIADH, and porphyria. Many drugs may interact with Glucotrol; patients should carefully check glucose levels and inform their doctors about what medications they are taking. There are no adequate and well controlled studies of Glucotrol in pregnant women. Glucotrol (glipizide) should be used during pregnancy or breastfeeding women only if the potential benefit justifies the potential risk to the fetus and infant. Safety and effectiveness of Glucotrol in children have not been established. Our Glucotrol Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking glipizide and call your doctor at once if you have a serious side effect such as: easy bruising or bleeding (nosebleeds, b Continue reading >>
Diabetes Drugs Tied To Pancreatic Cancer Risk
NEW YORK (Reuters Health) - A new study links the diabetes drug metformin to fewer cases of pancreatic cancer -- at least in women -- but finds other diabetes medications are associated with a higher risk of the disease. The differences in medication history among people who did or didn’t get pancreatic cancer were small, researchers said, and it’s unclear why the drugs might affect cancer risks in men and women differently. Still, the new finding is in line with previous research suggesting that metformin may decrease the risk of multiple cancers, said Dr. Peter Butler, a diabetes researcher at the University of California, Los Angeles David Geffen School of Medicine, who wasn’t involved in the new study. “One theme that seems to be coming through... is that the oldest drug we have for diabetes, metformin, is undoubtedly the best drug we have for diabetes,” he told Reuters Health. Pancreatic cancer is relatively rare as far as cancers go, but progresses quickly; most people don’t survive more than a couple years after diagnosis. The National Cancer Institute estimates that about 44,000 people will be diagnosed with pancreatic cancer in the United States this year, and close to 38,000 will die from the disease. Research has suggested that people with pancreatic cancer may have an increased risk of diabetes, but it’s unclear how diabetes -- and the drugs used to treat it -- may affect pancreatic cancer risks in previously cancer-free people. To help answer that question, Dr. Christoph Meier of the University Hospital Basel in Switzerland and his colleagues consulted a database of more than eight million people in the UK, including about 2,800 who were diagnosed with pancreatic cancer between 1995 and 2009. For each of those people, they found another six of Continue reading >>
Glipizide - Fda Prescribing Information, Side Effects And Uses
Glipizide tablets, USP is an oral blood-glucose-lowering drug of the sulfonylurea class. The Chemical Abstracts name of Glipizide is 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C 21H 27N 5O 4S; the molecular weight is 445.55; the structural formula is shown below: Glipizide, USP is a whitish, odorless powder with a pKa of 5.9. It is insoluble in water and alcohols, but soluble in 0.1 N NaOH; it is freely soluble in dimethylformamide. Glipizide tablets for oral use are available in 5 mg and 10 mg strengths. Inert ingredients are: colloidal silicon dioxide, lactose (anhydrous), microcrystalline cellulose, pregelatinized starch (corn) and stearic acid. The primary mode of action of Glipizide tablets in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans, Glipizide tablets appear to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which Glipizide tablets lower blood glucose during long-term administration has not been clearly established. In man, stimulation of insulin secretion by Glipizide tablets in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term Glipizide tablets administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. The insulinotropic response to a meal occurs within 30 minutes after an oral dose of Glipizide tablets in diabetic patients, but elevated insulin levels do not persist beyond the time of the meal Continue reading >>
Drug Injury Watch: Side Effect: Pancreatitis (inflammation Of Pancreas)
Severe Cases Of Pancreatitis And Sphincter Of Oddi Spasm Reported Even After Just The First Dose Of Viberzi, With Some Resulting In Patient Deaths (Posted by Tom Lamb at DrugInjuryWatch.com ) In March 2017 this document was issued, " FDA Drug Safety Communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder ". The following month, in April 2017, the drug company Allergan released a new Viberzi drug label, the details of which are set forth in this earlier article, " FDA Warns of Serious Pancreatitis Risk in Some Patients Taking Viberzi ", on our Drug Safety Developments blog. Viberzi (eluxadoline) is approved for use in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Viberzi works by activating opioid receptors in the gut to decrease bowel contractions, which leads to less diarrhea. It can also help to ease stomach-area or abdomen pain and improve stool consistency. According to the above-mentioned March 2017 FDA document: Hospitalizations related to pancreatitis, including deaths, have been reported with Viberzi in patients who do not have a gallbladder. Hospitalizations related to pancreatitis have also been reported in patients with a gallbladder. Symptoms of pancreatitis can occur after just one or two doses of Viberzi. __________________________________________________________________ In more detail, from the Data Summary part of this Viberzi FDA Drug Safety Communication: From May 2015, when Viberzi was first approved, through February 2017, FDA received reports of 120 serious cases of pancreatitis or death in the FDA Adverse Event Reporting System (FAERS) database. Seventy-six of these cases resulted in hospitalization, of which two patients d Continue reading >>
Will You Have Pancreatitis With Glipizide - From Fda Reports - Ehealthme
A study for a 50 year old man who takes Triamterene And Hydrochlorothiazide, Atorvastatin Calcium NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered. WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health. DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. You may report adverse side effects to the FDA at or 1-800-FDA-1088 (1-800-332-1088). If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date. Continue reading >>
Glipizide
Glipizide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Glipizide is in a class of medications called sulfonylureas. Glipizide lowers blood sugar by causing the pancreas to produce insulin (a natural substance that is needed to break down sugar in the body) and helping the body use insulin efficiently. This medication will only help lower blood sugar in people whose bodies produce insulin naturally. Glipizide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may occur if high blood sugar is not treated). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes. Glipizide comes as tablets and extended-release (long-acting) tablets to take by mouth. The regular tablet is usually taken one or more times a day, 30 minutes before breakfast Continue reading >>
Drug-induced Pancreatitis
The author, a member of P&Ts editorial board, is President and Chief Executive Officer of PRN Communications in New York City. She is also a Clinical Pharmacist in the New York Downtown Hospital Pharmacy Department and an Adjunct Assistant Professor at Touro College of Pharmacy in New York City. This article has been cited by other articles in PMC. There have been many published reports of potential cases of drug-induced pancreatitis (DIP). 1 3 When I was in my Doctor of Pharmacy training in Boston, the medical residents used the mnemonic FATSHEEP to remember the causes of DIPFurosemide, Azathioprine/Asparaginase, Thiazides/Tetracycline, Statins/Sulfonamides, Hydrochlorothiazide (a little overlap here), Estrogens, Ethanol, and Pentamidine. Although the latter two agents are rarely used today, the mnemonic was a good one because I still remember it after all these years. Some of the more common culprits for DIP include valproic acid, calcium-channel blockers, antipsychotic agents, sulindac (Clinoril, Merck), methyldopa, octreotide (Sandostatin, Novartis), 6-mercaptopurine, 5-aminosalicylic acid compounds, metronidazole (Flagyl, Pfizer), isoniazid, and corticosteroids. 1 , 3 , 4 Also implicated are the angiotensin-converting enzyme (ACE) inhibitors (the topic of the first Pharmacovigilance Forum column in the March issue of P&T); glucagon-like peptide-1 (GLP-1)based therapies such as liraglutide (Victoza, NovoNordisk) and exenatide (Byetta, Bydureon, Amylin); and the dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin (Januvia, Merck) and linagliptin (Tradjenta, Boehringer Ingelheim). 5 , 6 In fact, sitagliptin was the focus of an FDA alert on September 25, 2009. 7 This alert provided an update to the prescribing information and warnings related to 88 postmarketing cas Continue reading >>
Can Glipizide Cause Pancreatitis?
Lamisil vs Lotrimin Mucinex vs Sudafed Lactogen 1 Side Effects Evekeo vs Adderall Dexilant and Alcohol Treato does not review third-party posts for accuracy of any kind, including for medical diagnosis or treatments, or events in general. Treato does not provide medical advice, diagnosis or treatment. Usage of the website does not substitute professional medical advice. The side effects featured here are based on those most frequently appearing in user posts on the Internet. The manufacturer's product labeling should always be consulted for a list of side effects most frequently appearing in patients during clinical studies. Talk to your doctor about which medications may be most appropriate for you. The information reflected here is dependent upon the correct functioning of our algorithm. From time-to-time, our system might experience bugs or glitches that affect the accuracy or correct application of mathematical algorithms. We will do our best to update the site if we are made aware of any malfunctioning or misapplication of these algorithms. We cannot guarantee results and occasional interruptions in updating may occur. Please continue to check the site for updated information. Continue reading >>
Is There Evidence To Support That Sulphonylureas Burns Out The Pancreatic Beta Cells?
The fact that Sulfonylureas release insulin by closingthe KATP channels,this effect may not persist if pancreas unable to synthesize insulin. since their action is pancreas dependent, we don't see effect from these drugs if-cells stop secreting insulin and the patients then have to inject insulin to control their blood sugar levels. In that case, when insulin release stops, it seems that sulfonylureas burnt the pancreas which may not be the fact. It is true that at present we do not have evidence that sulphonylureas burn out Beta cells . but it seems that when sulphonylurea is given it takesof the driving seat in its own hand which other wise remains with Glucose. that is the major disadvantage The concept that sulphonylureas "burn out" beta cells faster than other therapies or in fact speed up the natural history of beta cell destruction in type 2 diabetes has been proposed largely by the Pharma companies selling DPP4-Inhibitors and is a anotherinstance of manipulation by big Pharma to sell new drugs. In fact, as long ago as the UKPDS it was shown that the rate of beta cell apoptosis is exactly the same irrespective of which form of therapy is utilised, be it lifestyle alone, sulphonylureas, metformin of insulin. More recently, in a systematic review of the subject, Zhang et al (1)concluded that treatment regimens with sulphonylureas as a second-line agent resulted in the longest time of insulin independence compared with all other regimens and that included DPP4-I and GLP-1 agonists. So it appears clear that sulphonylureas do not have a detrimental effect on beta cell survival, notwithstanding the information supplied to us by the DPP4-Inhibitor companies. 1. Zhang et al. Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Diabetes C Continue reading >>
- Stem Cells Of Type 1 Diabetes Patients Transformed Into Insulin-Secreting Beta Cells; Research May Lead To New Therapy
- Woodford and Swinburn offer new evidence that type-1 diabetes is linked to the level of A1 beta-casein in most types of cows milk
- New evidence that type 1 diabetes is linked to the level of A1 beta-casein in most types of cow milk
